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An accumulating body of evidence has emerged in the last 
decade to suggest that gastrointestinal (GI) inflammation 
might be involved in the development of Parkinson’s dis-
ease (PD). Elevated levels of proinflammatory cytokines 
[3] and fecal markers of inflammation have been reported 
in PD patients [5]. Data from genetic studies further sup-
port the close relationship between PD and GI inflammation 
as PD and Crohn’s disease (CD) share common causative 
and susceptibility genes such as leucine-rich repeat kinase 
2 (LRRK2) and nucleotide-binding oligomerization domain-
containing protein 2 (NOD2) (reviewed in [2]). Two recent 
large epidemiological studies, by showing an increased risk 
of subsequent PD in patients with inflammatory bowel dis-
ease (IBD) when compared with non-IBD subjects, tie even 
closer together these two disorders [4, 7].
The mechanisms by which gastrointestinal inflammation 
might influence PD development or progression are still 
unclear. A recent report showed that viral-induced gastro-
intestinal inflammation is associated with alpha-synuclein 
upregulation in the upper gastrointestinal tract [6]. In the 
context of PD, this observation suggests that a sustained 
low-grade inflammation might increase alpha-synuclein 
expression and aggregation in the submucosal neurons 
whose terminal axons are only micrometers away from the 
gut lumen, thereby initiating or worsening the pathological 
process. The recent findings demonstrating both epidemio-
logical and genetic links between PD and IBD logically led 
us to study the expression levels and aggregation of alpha-
synuclein in the GI tract of IBD patients with either CD or 
ulcerative colitis (UC).
For biochemical analysis, a total of 34 subjects partici-
pated in this study: 10 CD and 12 UC patients with an active 
disease, as well as 12 healthy controls who had a normal 
colonoscopy for colorectal cancer screening (see suppl. 
Table 1 [Online Resource 1] for subjects’ demographics and 
treatments). IBD patients had 4 biopsies (2 in an inflamed 
and 2 in a non-inflamed area) taken during the course of a 
colonoscopy. Biopsies were analyzed by Western-Blot and 
filter-trap assay (see Online Resource 2 for further details 
on the methods). For immunohistochemical analysis, full-
thickness segments of colon containing the myenteric plexus 
were obtained from 8 IBD patients (4 CD and 4 UC) and 
from 4 controls who underwent colonic resection for dis-
ease management and non-obstructive colorectal carcinoma, 
respectively (Online Resource 2).
A significant 2.07- and 2.35-fold increase in the expres-
sion levels of alpha-synuclein protein was observed in the 
non-inflamed and inflamed area of CD patients when com-
pared to controls, respectively (Fig. 1a and suppl. Fig. 1 
[Online Resource 3]). By contrast, no significant differences 
were observed between UC patients and controls (Fig. 1b 
and suppl. Fig. 1 [Online Resource 3]). Filter-trap assays 
were performed in samples from 6 controls, 6 CD and 6 
UC patients to detect alpha-synuclein aggregates. Although 
our assay efficiently detected alpha-synuclein aggregates 
in a brain sample from a patient with dementia with Lewy 
bodies, it did not show any appreciable difference in the 
immunoreactivity for alpha-synuclein or phosphorylated 
alpha-synuclein between colonic samples from CD, UC 
and controls (Fig. 1c and suppl. Fig. 2 [Online Resource 
4]). Additional immunohistochemistry experiments showed 
that alpha-synuclein immunoreactivity was increased in 
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myenteric neurons of CD patients when compared to UC 
patients and control subjects (Fig. 1d, e).
Our results show that alpha-synuclein protein levels are 
increased in the colon of CD, but not of UC patients and 
that this upregulation is not associated with more protein 
aggregation. These findings further reinforce the possible 
link between IBD and PD and the causal role of gastroin-
testinal inflammation in the development of PD. They also 
outline the fact that despite being grouped under the term 
IBD and sharing overlapping symptoms and complications, 
UC and CD are two different disorders from a pathophysio-
logical point of view. While CD is primarily associated with 
T-helper type 1 immune responses, UC predominantly shows 
a characteristic atypical T-helper type 2 cytokine pattern [1]. 
It is, therefore, tempting to speculate that some of the proin-
flammatory cytokines and/or para-inflammatory responses 
that are activated in CD but not in UC are involved in the 
regulation of alpha-synuclein expression. Further in vitro 
Fig. 1  Expression levels and aggregation of alpha-synuclein in 
colonic biopsies from patients with Crohn’s disease (CD) and ulcera-
tive colitis (UC). a, b Colonic biopsies lysates from 10 CD patients, 
12 UC patients and 12 controls (C) (see suppl. Table  1 [Online 
Resource 1] for subjects’ demographics and treatments) were sub-
jected to immunoblot analysis using antibodies against total alpha-
synuclein (α-Syn MJFR1 IB) and PGP 9.5 (PGP 9.5 IB). For UC and 
CD patients, biopsies taken in non-inflammatory (NI, CD-NI and 
UC-NI) and inflammatory area (I, CD-I and UC-I) were analyzed 
separately. For one UC subject (#283), no biopsies were taken in 
the non-inflamed area. To ensure equal protein loading, membranes 
were probed with anti-β-actin antibody. Illustrative images are shown; 
raw immunoblots are provided in suppl. Fig. 1 [Online Resource 3]. 
Alpha-synuclein immunoreactive bands were measured, normal-
ized to the optical densities of PGP 9.5 and expressed as percentage 
of controls. Data correspond to mean ± SEM of 12 samples for con-
trol subjects (C), 12 samples for UC patients in the inflamed area, 11 
samples for UC patients in the non-inflamed area and 10 samples for 
CD patients in both inflamed and non-inflamed area, **p < 0.005. c 
Colonic biopsies lysates from 6 UC and CD patients and 6 controls 
(C) were subjected to filter-trap assay with cellulose acetate mem-
brane using antibodies against total alpha-synuclein (α-Syn MJFR1 
IB) and phosphorylated alpha-synuclein (℗-α-Syn IB). Illustrative 
images are shown, raw results are provided in suppl. Fig. 2 [Online 
Resource 4]. Phosphorylated alpha-synuclein immunoreactive spots 
were measured and expressed as percentage of controls. d Anti-alpha-
synuclein Syn-1 and anti-β-tubulin III antibodies were used to detect 
alpha-synuclein in the myenteric ganglia in CD and UC samples 
and in control subjects. Scale bar is 50  µm. e Quantitative analysis 
of alpha-synuclein immunofluorescence in the myenteric plexus of 
CD, UC patients and controls. Data are shown as corrected mean gray 
value normalized to controls and presented as mean ± SEM, n = 18, 
22 and 26 myenteric ganglia for control, CD and UC group, respec-
tively. *p < 0.05, CD vs C, #p < 0.05, CD vs UC
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studies are definitely needed to identify these signaling path-
ways and to study if they are shared between the central and 
enteric nervous system. Such an approach should help us 
better understand the role of systemic inflammation in PD.
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